News | September 14, 2023
Zydus receives EIR for injectables manufacturing facility at Zydus Biotech Park, Ahmedabad
The inspection was a cGMP Inspection and had ended with NIL observations
The inspection was a cGMP Inspection and had ended with NIL observations
In 2030 over 50% of FDA approvals will involve AI discovered and developed drugs
Low-leveraged balance sheets, sizeable liquidity to keep credit profiles stable
Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris
This is a strategic acquisition for Cipla South Africa to unlock the future growth opportunities in the South African market
Amgen will be prohibited from leveraging its drug portfolio to disadvantage rivals and will be required to seek prior approval before acquiring related products
Robots make it to the healthcare conference panel, reflecting the future potential of technology
KNISS has established a solid foundation of trust in the customers' minds, delivering high quality Products uncompromisingly.
Jupiter has filed its draft herring prospectus (DRHP) with the market regulator in May this year, to float its IPO
The offer for sale comprises of up to Rs. 383 crore by Vishal Rakesh Agrawal, up to Rs. 383 crore by Rahul Rakesh Agrawal, and up to Rs. 134 crore by Geetganga Investment
Subscribe To Our Newsletter & Stay Updated
